Barclays lowered the firm’s price target on Cellectis (CLLS) to $4 from $5 and keeps an Overweight rating on the shares. The company’s Q1 was largely incremental with key pipeline programs on track, the analyst tells investors in a research note. The firm says Cellectis has a cash runway into the second half of 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS: